Glenn Dranoff of the Dana-Farber Cancer Center, collaborating with Somatix Therapy Corp, presented interim Phase I/II data for Somatix' GVAX cancer vaccine for advanced melanoma at the Molecular Medicine Society conference in Washington DC, USA. Dr Dranoff noted that he had observed evidence of local and systematic antitumor activity and some tumor cell death in patients with metastatic disease.
The GVAX cancer vaccine is Somatix' lead product in development. The company creates the vaccine by genetically-modifying either a patient's own cells or a tumor cell line to produce GM-CSF. It has received US approval to proceed to Phase III testing. The incidence of melanoma has been steadily increasing, and other companies are also researching in this field. And as reported last week, Ribi ImmunoChem has already filed for approval for its melanoma vaccine Melacine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze